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Abstract: Periodontal diseases involve injuries to the supporting structures of the tooth and, if left
untreated, can lead to the loss of the tooth. Regenerative periodontal therapies aim, ideally,
at healing all the damaged periodontal tissues and represent a significant clinical and societal
challenge for the current ageing population. This review provides a picture of the currently-used
biomaterials for periodontal regeneration, including natural and synthetic polymers, bioceramics (e.g.,
calcium phosphates and bioactive glasses), and composites. Bioactive materials aim at promoting
the regeneration of new healthy tissue. Polymers are often used as barrier materials in guided
tissue regeneration strategies and are suitable both to exclude epithelial down-growth and to allow
periodontal ligament and alveolar bone cells to repopulate the defect. The problems related to
the barrier postoperative collapse can be solved by using a combination of polymeric membranes
and grafting materials. Advantages and drawbacks associated with the incorporation of growth
factors and nanomaterials in periodontal scaffolds are also discussed, along with the development of
multifunctional and multilayer implants. Tissue-engineering strategies based on functionally-graded
scaffolds are expected to play an ever-increasing role in the management of periodontal defects.
Keywords: dental materials; periodontal tissue engineering; dental implants; bioceramics; polymers;
composites; bioactivity; nanotechnology; nanomaterials
1. Current Strategies in Periodontal Tissue Engineering
The primary goal of periodontal tissue engineering is to regenerate the supporting tissues of the
tooth. Tooth loss can be the result of trauma or periodontal diseases, including gingivitis, periodontitis,
or age-related tissue decay. There are two distinct aims in periodontal tissue engineering strategies,
which include the formation of new alveolar bone and connective tissue (cementum and periodontal
ligament). If left untreated, periodontal disease invariably leads to the loss of the tooth, and it has
been estimated that about 10% of the global population is affected by severe periodontitis [1]. Statistics
have shown that above 300,000 dental implants are placed annually only in the USA, and this number
is expected to further increase in the next decade [2–4]. Tooth replacement by using titanium dental
implants is currently a routine procedure with a success rate of around 98%; however, it still suffers
from some limitations. In this regard, it cannot be ignored that the positive outcome of a titanium screw
insertion mainly depends on the quantity and quality of the patient’s alveolar bone which can support
the implant in the extraction site [5]; hence, the development of suitable strategies for the regeneration
of hard tissue is of paramount importance in dental surgery. In the last decades, the treatment of soft
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tissue defects has also gained increasing attention in order to prevent advanced forms of periodontal
injuries related to mucogingival anomalies and better satisfy the aesthetic demands of patients [6].
Periodontal regeneration is recognized as one of the primary clinical disciplines which has
benefitted from the novel technologies based on tissue engineering [7]. Biomaterials, bioactive
molecules (e.g., growth factors), and (stem) cells are the three critical factors behind the management
of periodontal disease (see Figure 1). Current therapies for periodontal tissue repair and regeneration
include conservative approach, radicular conditioning, bone grafting/substitution, and guided tissue
regeneration (GTR), as well as a combination of the two last strategies.
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Conservative therapy includes the surgical debridement of the periodontal pathogenic
microorganisms, mineralized deposits on the root surface, infected cementum as well as all the
injured/necrotic tissue parts [8,9]. This procedure is fundamental to allow periodontal healing
and commonly precedes any type of reconstructive strategy. This approach relies on the concept
that patients’ fibroblasts from the epithelium are the cells possessing the fastest growth ability; thus,
increasing the distance between the epithelial layer and the wound by surgery allows slower connective
tissue formation and prevents fibroblasts from achieving the radicular surface before the osteogenic
cells. The importance of debridement was first reported by Prichard [10] in the late 1950s and,
since then, the results have always confirmed the need for reaching specific clinical conditions that
include lack of inflammation as well as a minimized and under-controlled bacterial plaque. These
situations are ideal for allowing the regeneration of the periodontal tissue [11–13].
As a direct result of periodontal disease or after a surgical procedure, the root surface
could be directly exposed to the oral environment that is invariably full of various types of
bacteria. The radicular surface is a suitable substrate for bacterial adhesion and biofilm formation,
with the associated risk of the increased inflammatory response [14]. In these cases, chemical
conditioners are often used to obtain a more biocompatible surface for healthy cells [8,15]. Citric acid,
ethylenediaminetetraacetic acid (EDTA) and tetracycline are the most commonly-used acids, the role
of which is to decontaminate the surface from bacteria and endotoxins. Furthermore, the surface of
collagen fibers is exposed to the etching of detergents, thereby potentially providing a good condition
for adhesion of cells that are responsible for tissue regeneration [8]. Despite the minor invasiveness,
the actual superiority and clinical benefits of using non-surgical disinfection compared to surgical
debridement still remains controversial [16].
The above-mentioned techniques alone promote periodontal repair rather than periodontal
regeneration; a good repopulation of the defect site can be achieved by implanting bone grafting
materials (after debridement) that stimulate new bone formation [17]. Tissue regeneration is often
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achieved by combining bone grafting materials and guided tissue membranes, with or without the
use of specific growth factors. The use of stem cells is now under development and is considered as
a more recent tactic [18,19], the potential of which could allow overcoming the well-known major
drawbacks of most synthetic biomaterials, i.e., the lack in the induction of tissue formation. Despite
the great promise of stem cells, there are still many safety, regulatory, and ethical issues concerning
their clinical use.
2. Inside Periodontal Regeneration—A More In-Depth Overview
At present, the majority of tissue-engineering strategies applied to treat periodontal diseases
aim at regenerating the alveolar bone through the implantation of suitable scaffold-based constructs.
Specifically, periodontal regeneration relies on four basic paradigms [20]:
(i) Implanted material (scaffold) acts as a three-dimensional (3D) template supporting new
tissue growth;
(ii) Cells are the primary building blocks of the reconstructive strategies of periodontal tissue
thanks to their proliferation and differentiation;
(iii) Bioactive molecules (i.e., growth factors) promote cell activity that results in improved cell
proliferation and differentiation;
(iv) The blood supply delivers oxygen, nutrients, and essential factors to tissue, and thus promotes
the growth of newly formed tissue and helps to maintain homeostasis inside the 3D scaffold.
The healing process of the periodontal tissue is traditionally achieved by tissue repair; however,
the advent of tissue engineering and regenerative medicine provides new possibilities in this regard [7].
Based on the definition, repair process includes the healing of a wound by the growth of tissue that,
however, may not fully restore the fine microstructure and, consequently, the function of the lost
tissue [21,22]. Moving a step forward, regenerative medicine uses tissue-engineered constructs to
restore the original architecture and function of the injured tissue [23]. Two main objectives are
simultaneously pursued in the current periodontal tissue engineering approaches, including (i) the
stimulation of the growth of the key surrounding tissues by applying barrier membranes and bone
grafting materials and (ii) the prevention of the growth and proliferation of undesired cell types like
epithelial cells [24].
The periodontium in its native form is comprised of various parts including alveolar bone,
cementum, junctional epithelium, and a gingival connective attachment. This tissue is a result of the
interaction between mesenchymal and epithelial cells in the embryo [25,26]. A series of independent
and subsequent events need to complete the periodontal regeneration, which include osteogenesis,
cementogenesis, and connective tissue formation [27]. It has been well documented that various
physico-chemical and mechanical stimuli can cause appropriate responses by the cells during the
healing process. The type of cells used in regeneration controls the quality of the healing process since
they are responsible for repopulation of the wound first [24]. In the case of the periodontal regeneration,
four distinct cell types compete—namely, periodontal ligament cells, alveolar bone cells, cementoblasts,
and epithelial cells. Among these cells, the first three types are responsible for regenerating the
periodontal tissue, while the last type—i.e., epithelial cells—are responsible for soft tissue regeneration.
It is worth mentioning that the higher migration rate of epithelial cells (10 times faster) in comparison
to the other periodontal cell types is the reason of observing the formation of the long junctional
epithelium in the periodontal therapy [28]. Infiltration of epithelial cells inside the defect can promote
repair by the formation of unusual architecture with a loss of function [29]. Therefore, guided tissue
membranes are implanted to limit the infiltration of the epithelial cells [30]. If epithelial cells are
ruled out from the wound, other cell types with regenerative potential are thus allowed to become
established, and epithelial down-growth can be successfully prevented [24]. A combination of bone
graft materials, promoting the migration and differentiation of osteoblast cells, and GTR is the most
commonly-used approach for achieving an optimal periodontal regeneration [31,32]. Two reasons
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have been identified behind this synergic activity, i.e., the biological effects of bone grafts and the
“Melcher hypothesis”, which explains the importance of cells used for the periodontal regeneration.
According to this hypothesis, the origin of cells dictates the nature of the attachment in periodontal
healing and the complete periodontal regeneration may be achieved when we apply cells with an
origin from the periodontal ligament and the perivascular bone cells [8,33,34].
The biological actions induced by bone grafting materials can be divided into three interrelated
healing processes: osteogenesis, osteoconduction, and osteoinduction [35]. The autologous bone
graft is the ‘gold standard’ option to achieve osteogenesis [36]. In this case, the undifferentiated and
pluripotent cells derived from the transplanted material differentiate into the bone-forming cell lineage,
i.e., osteoblasts, which will form new bone [37]. Osteoconduction refers to the ability of a biomaterial
to act a suitable surface for guiding the bone growth by pre-existing preosteoblasts/osteoblasts [35,38].
Osteoinduction is usually identified as a specific property of materials regarding the induction of the
differentiation of the host osteoprogenitor cells into osteoblasts [39]. In this case, the graft material
excludes the undifferentiated connective cells and just induces the differentiation and proliferation
of osteoprogenitor ones, thus leading to new bone formation [35,40,41]. The Melcher hypothesis also
points out the importance of barrier materials for enabling cell migration from the connective tissue
to avoid the repair process [24,32,42]. Numerous previously performed animal studies clarified the
efficacy of non-resorbable and resorbable membranes for GTR [32,42].
Three correlated steps are involved in the healing process of periodontal tissue injuries. The first
step is the epithelization of the internal face of the flap that forms the so-called long epithelium
attachment. The maturation of the connective tissue is the second step in which we observe the
formation of the so-called connective attachment. The final step is related to the recovery of bone
architecture and the periodontal ligament at the level of alveolar bone and in the deepest point of injury.
The morphology of the structure of newly formed tissue indicates whether repair or regeneration
took place [7]. In the case of repair, fibroblasts mostly are involved in the healing process instead of
osteoblasts, thus the deposition of the osteoid matrix and new bone formation are inhibited [21,22].
On the other hand, regeneration involves the complete recovery of both the structure and the function
of the periodontal tissue [7,43].
Despite the implementation of this approach, the success of periodontal regeneration depends
on the capacity to control local infections, that are caused by microbial pathogens contaminating
periodontal wounds [44–46]. The removal of necrotic tissue or a zone with acute infection are often
identified as the major complications of periodontal defects and are high-risk places for bacterial
growth and re-infection of new tissue [47,48]. Hence, there is a need for implementing appropriate
strategies to regenerate the periodontal tissue and restrain bacterial growth [49]. There are critical
limitations in front of the currently-available strategies (e.g., conventional systemic antibiotic therapy)
applied for reducing the risk of wound infection, including the systemic toxicity in the body which can
lead to the need of hospitalization for monitoring [50–53]. In order to overcome these problems, several
research groups are working on advanced systems able to release low dosage of antibiotics directly in
situ (see Figure 2) [54–60]. Promising approaches for avoiding bacterial adhesion and minimizing the
side effects of systemic antibiotics include the coating of titanium implants with antiseptic molecules,
the implant modification with functional groups exerting a bactericidal action, and the use of specific
signaling molecules which selectively act as bactericidal substances [55,61–63].
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infection prevention. The functionalization of the ceramic scaffold with a pectin-chitosan hydrogel
allows the control of antibiotic release, inhibits bacterial proliferation and biofilm formation,
and promotes osteoblast proliferation. Optical and scanning electron microscopy pictures courtesy of
Giorgio Iviglia.
3. Biomaterials for Periodontal Tissue Engineering
Bone grafting materials are widely used in periodontal tissue engineering in order to augment the
alveolar bone and provide adequate mechanical support for a future, permanent implant. They include
materials of biological (e.g., osseous transplants) or synthetic origin and are made available to dental
surgeons in different forms and shapes, such as particles, 3D scaffolds, injectable pastes or composites
in combination with polymeric materials. Given that microbial infections play a crucial role in the
evolution of periodontal diseases and can have a devastating effect, in the last years some attempts to
develop new dental materials with antibacterial properties have been carried out in order to control
the infection and increase the implant success rate.
3.1. Bone Transplant Materials
3.1.1. Autografts
Autologous grafts are currently considered the ‘gold standard’ solution for bone replacement [64].
Autografts are ti sue portions tra splanted from one part of the body t another in the same patient.
If the alveolar bon defect is small, the autologous aterial is usually harvested intraorally fro
the extraction sockets, edentulous ridges, ramus, symphysis, tubero ity, or from the surrounding
buccal plate. In the pre enc of large bone defects, autografts are typically obtained from extra-oral
areas, such as the iliac cr st, tibia, or kull; inv riably, this latter approach is more stressful to the
patient due to the need for a second-site surgery. The implant survival rate for utologous bone grafts
was reported to v ry in the range of 76–100%, with the worse result for iliac crest bone compared
to calvarial [65–68]. Other stu ies, however, reported that the results obtained with intraor l
grafts wer similar to th se observed with extra-oral sources [67,69]. A robust c mparison among all
these data is not possible due to donor site variability and often unpredictable complications; hence,
the debate about the ‘optimal’ autologous material still lingers on and, at pr sent one cannot claim
that a particular technique is clearly superior to another [70].
The significant advantages of using autografts are that they are osteogenic, prevent disease
transmission and are relatively inexpensive. Clinical tests generally sh w d excellent p rio ontal
regeneration with the formation of new cem ntum; for example, Schallhorn and colleagues use iliac
crest grafts for the manage ent and treatment of infrabony defects with g od results (up to 4-mm
bone healing) [71]. Major drawbacks include the need for a second surgery and the risk of possible
co plications t the harvesting site, such as infection a d postoperative pain [72]. Furt rmore,
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the limited availability of autologous material is an additional issue that makes this approach less
attractive to treat large injuries.
3.1.2. Allografts
An allogenic graft is a biologic material harvested from a donor of the same species with a
different genotype. The key advantage of allografts is the elimination of a second surgical procedure
and tissue resource constraints [6]. This type of graft is usually available in tissue banks that process
the donor (cadaver) tissues; depending on how the allografts are treated, the tissues can be divided into
freeze-dried bone allografts (FDBAs) and decalcified freeze-dried bone allografts (DFDBAs). Allografts
have the significant disadvantages to potentially elicit a foreign body immune response and carry the
risk of disease transmission, albeit a robust safety and regulatory system has been developed in the last
years at the international level [73–75]. Despite the mentioned limitations, the researchers and clinicians
have recognized allografts as relatively high reliable sources for reconstructive applications since they
can serve as osteoconductive or even osteoinductive materials based on the remaining proteins into
their matrix [76]. While decalcification process of allografts can result in exposing bone morphogenetic
proteins (BMPs) that are osteoinductive molecules for bone regeneration, this procedure is the main
reason for the high resorption rate of allografts as compared to autografts, which can lead to less
effective scaffolding properties.
Several studies compared the clinical outcomes associated with FDBAs and DFDBAs. Yukna et al.
performed animal studies in which both FDBAs and DFDBAs were placed into surgically-created
infrabony defects and evaluated by histological analysis [77]. After three months, FDBAs showed
higher new bone formation than DFDBAs. Altiere et al. [78] and Blumenthal et al. [79] also reported
excellent results as regards new bone formation after using FDBAs. The high variability of these
types of grafts was also pointed out: Mellonig showed that DFDBA exhibited similar bone-filling
percentage compared to FDBA in one study [80] while observing higher bone-filling percentage in a
previous study where FDBA was mixed with autologous material [81]. Another disadvantage of such
an approach is the high material cost compared to other options like xenografts [82].
3.1.3. Xenografts
Xenogenic materials are bone substitutes obtained from other species (typically bovine and
porcine grafts) and transplanted into humans. In the past, storage of these grafts in tissue banks
was often preferred as it is possible to extract larger amounts of bone from animals with a specific
microstructure as compared to auto- and allografts. Since the main disadvantage of xenografts is their
antigenicity, animal tissues should be carefully processed to remove all organic components. There
are many commercial products based on this process, such as Geistlich BioOss® particles (Geistlich
Pharma, Wolhusen, Switzerland) from the bovine source, which is considered one of the reference
products in dental applications worldwide.
However, in spite of the positive results obtained from studies conducted on xenografts, it cannot
be ignored that the rate of graft resorption and bone regeneration with these materials might be
unpredictable [83]. Taschieri et al. observed a periodontal healing rate of 78% in patients implanted
with bovine-derived bone grafts after a one-year follow-up but did not detect any difference as
compared to non-treated lesions where the only debridement was carried out [84]. In another
study, eight infrabony defects were treated with xenografts, and the results showed that seven
defects successfully healed with actual bone regeneration, while one defect healed by the growth of
non-osseous tissue [85].
Being stored in tissue banks and made promptly available, xenografts are advantageous over
autografts as they require a single surgical procedure; on the other hand, some people might refuse to
be implanted with these animal-derived materials due to ethical and religious concerns.
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3.2. Need for Alternatives to Bone Transplantation
The osseous grafts described above suffer from different disadvantages such as the need for
second-site additional surgery (autografts), the risk of disease transmission (allograft and xenografts),
limited availability (autografts), and unpredictable results (xenografts). In recent decades, man-made
biocompatible materials have gained increasing interest thanks to their attractive characteristics,
including controlled degradation, osteoconductivity, and/or osteoinductivity, customized mechanical
properties, and relatively easy shapability to match the defect dimensions [86]. Non-transplant
materials used for periodontal tissue regeneration typically belong to the classes of ceramics and
polymers or can be the result of their mixture [64,87]. Bioceramics include calcium phosphates, calcium
sulfate, and bioactive glasses [88,89]. Polymers can be of natural (e.g., modified polysaccharides,
polypeptides) or synthetic origin (e.g., poly(glycolic acid), poly(L-lactic acid)). Natural and synthetic
polymers are often combined with ceramics for obtaining composite biomaterials with superior
osteoinductive properties, enhanced mechanical performance, tunable degradation rate, and better
cell adhesion [64,86,90].
3.3. Bioceramics
3.3.1. Calcium Phosphates
Calcium phosphate materials have a long history and the early studies about their biological
significance date back to 1920 [91]. Since then, a huge amount of knowledge and data related to
their chemistry, formulations, and properties has been produced and consolidated [92–94]. Calcium
phosphates are very popular in bone and dental tissue engineering applications due to their
compositional affinity with the mineral phase of natural bone. In general, these materials tend
to induce a biological response which is similar to that generated during bone remodeling, i.e.,
resorption of the old bone and, in parallel, the formation of new bone. Since calcium phosphate
grafts are chemically similar to the natural bone, their degradation products are non-toxic and can be
naturally metabolized by mammals [95]. Implantable calcium phosphates are available as solid pieces,
3D porous scaffolds, granules, and pastes or cements. Hydroxyapatite (HA), tricalcium phosphates,
and their different combinations are recognized as the most commonly-used calcium phosphates in
periodontal reconstructive strategies.
HA (Ca10(PO4)6(OH)2)) is the most abundant inorganic component of natural bone (around
65% of its inorganic phase) and has found a lot of applications as bone filler in the clinical practice.
Many studies have been focused on the interaction between HA implants and bone [96–100]. A direct
chemical bond was reported to form between osseous tissue and HA graft, which gives rise to a kind of
bone matrix on the implant surface. This newly-formed matrix is composed of both globular mineral
deposits and an organized network of collagen fibers, which may enhance the interfacial bonding [101].
Osteoblasts can attach on the HA surface and start forming mineralized osteoid, which then matures
into fully mineralized bone [102]. Apatite crystals—which may also incorporate other ions like
carbonate groups—appear on the surface of implanted HA grafts and exhibit a nano-crystalline
morphology mimicking the biological apatite of the alveolar bone [103]. HA is osteoconductive but
has a very slow degradation rate which limits its use alone [104].
Due to this reason, the interest in tricalcium phosphate (TCP) materials has rapidly increased
in recent years. The degree of solubility mainly depends on the Ca-to-P ratio (the rate of dissolution
increases with decreasing Ca/P ratio) as well as on the crystallographic structure, thus producing the
following progression: HA < β-TCP  α-TCP).
The most attractive TCP phase in biomedicine is the β one, which has clearly shown good
biocompatibility and osteoconductive properties [90]. Interestingly, β-TCP exhibits degradation
kinetics comparable to the rate of new bone growth and regenerative properties similar to those of
autologous bone grafts [105]. However, β-TCP has poor mechanical properties and, therefore, its use
as implant material is typically recommended only in low-bearing applications and in particle form.
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Furthermore, the resorption rate could be too fast in very large bone defects. β-TCP resorption in vivo
is based on two main mechanisms, i.e., the dissolution occurs due to the lixiviation by biological fluids
or the action of osteoclast cells; a coexistence of the two was also hypothesized [106]. It was also
shown that, as dissolution proceeds, the osteoclast activity decreases over time due to the high amount
of calcium ions released into the implant surroundings (modulatory effect on cell behavior) [107,108].
The dissolution rate of the material depends on many parameters such as the sintering process, micro-
and macro-porosity, and purity of the raw material [109]. A valuable strategy to control the degradation
rate is to produce multiphasic ceramics by mixing different calcium phosphates according to a ratio
which fits the needed characteristics [110,111].
A suitable grafting material for periodontal tissue engineering should be osteoconductive, be able
to sustain the load applied on the defect site as new bone grows, and safely dissolve without
producing any toxic ionic species for the surrounding tissue [64,112,113]. The balance between HA
and β-TCP is a crucial point to obtain adequate mechanical strength, suitable degradation kinetics,
and osteointegration in biphasic calcium-phosphate ceramics. Several studies were performed in order
to assess the best HA-to-β-TCP ratio, but the results are difficult to robustly compare since many
variables affect the conclusions from one to another group of researchers [110,114,115]. For example,
it has been clarified that the degradation rate, as well as the mechanical and the biological properties,
are extensively controlled by the sintering parameters, the mixing method, the raw material source
as well as the final shape of the product (e.g., powders, granules, paste, 3D scaffold, and so on).
An interesting study carried out by Yamada et al. [106] compared the osteoclastic response to different
biphasic calcium phosphates depending on the β-TCP-to-HA ratio (wt %), which was changed from
100% of β-TCP to 100% of HA through 75/25 β-TCP/HA and 25/75 β-TCP/HA. Resorption lacunae
were observed on pure β-TCP and 75/25 β-TCP/HA material; on the contrary, the material containing
higher amounts of HA was not resorbed by osteoclasts. The authors found that the lobulated lacunae
formed on the surface of biphasic ceramics are similar to those presented on the natural bone. Moreover,
the high dissolution rate of pureβ-TCP and the totally absent osteoclast activity on the pure HA suggest
that the use of a combination of β-TCP and HA (as a biphasic material) provides a proper condition
for osteoclasts to act more naturally. As new bone deposition by osteoblasts is strongly related with
osteoclastic resorption during bone remodeling, biphasic calcium phosphates promote the creation
of a surface similar to that of the native bone, and hence presumably the dissolution/precipitation
process which occurs during the osteoclastic activity favors the formation of a chemical bond between
bone apatite and similar apatite formed on the ceramic surface. By changing the proportion between
HA and β-TCP, it is feasible to control the degradation rate of the bone graft and, accordingly, the bone
formation. The mechanical properties of grafting materials are controlled by the amount of β-TCP
and HA of the biphasic material; in particular, a material with a high percentage of β-TCP shows
poor mechanical properties. Morra et al. [116] recently developed a biphasic granulate bone filler with
a HA/β-TCP weight ratio of 75/25; after being implanted in rabbits, this graft elicited an excellent
new bone formation without any inflammatory response. The mechanical properties were shown to
depend not only on the composition but also on the geometry (e.g., the presence of macropores) and
process parameters (i.e., sintering temperature and time), thus opening a broad range of possibilities
for optimizing the properties of these bone grafts for use in periodontal tissue engineering.
3.3.2. Bioactive Glasses
In bone tissue engineering, a bioactive material has been traditionally defined as a material that
undergoes specific surface reactions in vitro and in vivo, promoting the formation of a HA-like layer
which allows a strong bond between host bone and grafting material to occur [87,117,118]. This ability
was also referred to as osteostimulation by Schepers and Ducheyne [119]. Recent studies have revealed
that bioactive glasses are osteoinductive materials, too, as they can induce osteoprogenitor cells to
migrate into the structure of the graft and can promote cell differentiation by affecting the gene
expression of undifferentiated cells [120–122]. These exceptional properties have been associated with
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the release of therapeutic ionic species, mainly silicate and calcium ions, which can stimulate bone
cells towards paths of regeneration and self-repair [123,124].
The most commonly-used bioactive glass with a 50-year history is the well-known 45S5 Bioglass®
(45SiO2-24.5Na2O-24.5-CaO-6P2O5 wt %), which exhibits a relatively low SiO2 content, high Na2O,
and CaO content, and high CaO/P2O5 ratio to favor the reactivity with biological fluids [125].
This composition promotes the formation of a bone-like nano-crystalline HA layer on the surface
of the glass, which can therefore firmly bond to the host bone [126,127]. 45S5 glass particulate,
commercially marketed as PerioGlas® (NovaBone Products LLC, Alachua, FL, USA) in dental
applications, was proved able to inhibit the down-growth of epithelial cells and to promote the
regeneration of alveolar bone [128,129]. Bioactive glass particles were also added to the autologous
material in large infrabony defects, where the amount of grafting material needed is large, and there is
the need for high mechanical properties [130].
More recent studies in small animal models have proposed the use of borosilicate glasses to
regenerate bone as they are characterized by faster apatite-forming and bone-regenerative abilities
than silicate glasses [131]; however, no studies dealing with the specific application of these glasses in
periodontal tissue engineering have been reported yet in the literature.
3.3.3. Calcium Sulfate
Calcium sulfate, which is also known as ‘plaster of Paris’, was used as a tissue augmentation
material for the first time in 1892 to fill cavities caused by tuberculosis [132]. Since then, this material
has been widely used in orthopedics and dentistry to fill bone defects [133]. Three different forms of
calcium sulfate exist depending on the number of water molecules inside their crystalline structure,
namely the anhydrate, dehydrate, and hemihydrate [134]; the last material, being quickly soluble,
is typically used in medical grade products [135].
After being completely degraded in biological fluids, calcium sulfate leaves behind calcium
phosphate deposits that stimulate bone growth [133,136]. Moreover, it has been documented that the
porosity and hygroscopic properties of calcium sulfate are the key factors allowing adsorption and
infiltration of platelets to stimulate the formation of bone and new blood vessels (i.e., angiogenesis). It is
worth noting that no adverse reaction (e.g., immunogenicity) has been reported regarding by-products
of calcium sulfate, and it could be classified as a short-term space maintainer. Calcium sulfate is
preferably used in the forms of moldable paste or putty, and there are many publications dealing
with its clinical effectiveness and safety in filling periodontal defect [137–139]. Furthermore, calcium
sulfate has been used as a tentative barrier material to prevent ingrowth of soft tissues, even if its
tendency to rapidly dissolve limits its efficacy in the short term [140,141]. Gitelis and Brebach also
impregnated calcium sulfate pellets with antibiotics in order to develop an implantable system for
local drug delivery [142].
If good biological properties and relative inexpensiveness have encouraged the use of calcium
sulfate as a graft material for many years, the advent of other biomaterials with more controllable
solubility and predictable fate in contact with blood and saliva has progressively reduced its use
over the last decade [136,143]. In order to overcome the problems associated with fast resorption,
calcium sulfate has also been combined with other materials, such as calcium phosphates, thereby
achieving a more stable structure and a finer control on the resorption kinetics [138,139,141]. Other
approaches involve the production of biphasic calcium sulfate, in which dehydrate and hemihydrate
types are mixed to decrease the dissolution rate and make a rigid matrix post-implantation [144].
Today, the primary uses of calcium sulfate and its composites in dentistry and maxillofacial surgery
are in the field of injectable bone fillers for sinus augmentation and alveolar bone regeneration in small
periodontal defects [145].
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3.4. Polymers
The use of soft moldable materials in periodontal tissue engineering is a widespread practice.
They can be applied as barrier membranes, hydrogels, and in combination with glass and ceramics.
Natural polymers can mimic the extracellular matrix (ECM) of the bone tissue and allow cell infiltration,
proliferation, and new bone formation [146]. Natural polymers possess a few properties, including
elasticity, hydrophilicity, biodegradability, moldability, and biocompatibility, which are very suitable
for tissue engineering applications. However, there are some disadvantages, too, including source
variability, immunogenicity (if they are not pure), and poor mechanical properties (compared to bone)
when used alone.
3.4.1. Collagen
Collagen is the most popular among the natural materials for tissue engineering since it has
proven biocompatibility and ability to promote wound healing [147]. It may be extracted from several
allogenic sources being the most common structural protein found in the ECM of different connective
tissues such as bone, cartilage, muscle, tendon, and skin [148]. Up to now, a large number of studies
have been conducted on type I collagen that is the most abundant form of collagen in the body
and forms the major component of periodontal connective tissue [147,148]. Collagenous materials
degrade via enzymatic lysis, and the resulting by-products are biocompatible and do not cause any
inflammatory response [149]. Collagen is widely used in barrier membranes as guiding material for
tissue regeneration, in hydrogel sponges and as a coating material on ceramic scaffolds or metallic
dental implants to mimic the natural component of bone ECM, thus providing the underlying substrate
with a biomimetic surface (Figure 3) [79,150]. The tensile strength and elastic modulus of collagen
can be improved by crosslinking agents, such as (1-ethyl-3-(3-dimethylaminopropyl) carbodiimide
hydrochloride) (EDC), glutaraldehyde, and tannic acid. Crosslinking of collagen fibers typically
improves the mechanical properties and decreases the degradation rate, but it can have a negative
impact on cell response since most of the chemical crosslinking agents are toxic [151,152].
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3.4.2. Chitosan
Chitosan is a natural linear polysaccharide derived from chitin that is commonly extracted
from the crustaceous exoskeleton and is composed of randomly distributed β–(1,4)–glucosamine and
N-acetyl-D-glucosamine [153]. White mushrooms are other sources of chitosan which may be preferred
to eliminate any animal-related immunogenic and ethical issues; however, the extraction process is a
bit more expensive, and the yield is lower.
The widespread use of chitosan in bone tissue engineering applications and pharmaceutics is
related to its attractive characteristics including biocompatibility, antibacterial activity, and the ability
to promote cell adhesion, proliferation, and differentiation [154,155]. Furthermore, chitosan has a
backbone similar to that of glycosaminoglycans, the major components of bone ECM [156]. After being
implanted in patients with periodontitis, chitosan could reduce gingival inflammation thanks to its
antimicrobial properties [157].
Many biomedical applications involve the combination of soft chitosan with stiff, high-strength
bioceramics to produce porous foams or composite pastes [158,159].
Interestingly, chitosan exhibits a poly-cationic nature allowing the creation of ionic
interactions with other poly-anionic materials, thus generating the so-called polyelectrolyte (PEI)
hydrogel [153,160–162]. These properties are used to produce smart materials for controlled drug
release, especially for use in the intestinal tract: in fact, this ionic bond is pH-sensitive e and, therefore,
the drug release rate depends on the pH of the organ [160,163].
3.4.3. Pectin
Pectin is a natural anionic polysaccharide which is abundantly contained in citrus cell walls and
apple peel by-products and consists of a poly(D-galacturonic acid) chain with partly-methoxylated
carboxylic groups [164,165]. Although the use of pectin is a historical background in the food industry,
it has recently found some medical applications in bone tissue engineering and controlled drug release,
too [166,167]. The ionic crosslinking of pectin carboxylic groups can be achieved by calcium ions
to form the so-called “egg box” structure, where a divalent cation (Ca2+) is bonded with different
carboxylic anions [168,169]. Furthermore, a PEI structure can form as a result of the ionic interactions
with poly-cationic polysaccharides, as already observed for chitosan [170].
The major limitation of pectin is its fast solubility in aqueous media, which causes rapid
dissolution and when used as a drug carrier, a burst release of the therapeutic molecules [162].
In the attempt to overcome this problem, studies have been carried out to combine pectin with other
materials, such as chitosan, in order to increase the chemical resistance in water [161,163,171–173].
Pectin has also been used in combination with calcium phosphate particles, since it can mimic the ECM
and guide cell proliferation, or be applied as a surface coating in different biomedical applications,
such as antiadhesive surgical meshes [174–178].
3.4.4. Alginate
Alginic acid is a natural polymer extracted from brown algae or synthesized through bacterial
biosynthesis, which allows obtaining macromolecules with more controllable structure. Alginic acid
is identified as a linear copolymer made of (1,4)-linked β-D-mannuronate (M) and α-L-guluronate
residues (G) blocks [179]. The characteristics of the alginate material are determined by the amount
of the blocks composed of consecutive G and M residues [180]. Alginate is a suitable material for
biomedical applications due to its significant features including good biocompatibility, relatively
low cost, and simplicity of gelation [113]. However, alginate suffers from low mechanical strength,
like all other natural polymers, and need to be coupled with other materials, such as pectin, chitosan,
β-TCP, or bioactive glasses [161]. Alginate hydrogels and alginate/bioactive glass composites have
been experimented in periodontal tissue engineering and were found able to induce osteoblastic
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cell differentiation and enhance alkaline phosphatase (ALP) activity of human periodontal ligament
fibroblast cells [181,182].
3.4.5. Hyaluronic Acid
Hyaluronic acid (or hyaluronan) is a highly-attractive material for periodontal tissue engineering
since it is one of the natural glycosaminoglycans contained in the ECM of connective tissues,
with excellent potential for making scaffolds for tissue regeneration [183]. Hyaluronic acid is a linear
polysaccharide and, in dentistry, was shown to elicit anti-inflammatory and antibacterial effects in the
treatment of periodontal diseases [184].
The repeating unit of hyaluronic acid is composed by d-glucuronic acid bonded to
N-acetyl-d-glucosamine [185,186]. Hyaluronan exhibits hygroscopic and viscoelastic properties, which
allow the material to absorb a huge amount of water while maintaining conformational stiffness and
to fill the defect space, thus protecting the exposed tissue surfaces in periodontal surgery [186–188].
Furthermore, hyaluronic acid can act as a stable barrier against the penetration of viruses and bacteria
and elicit a bacteriostatic effect, which are key features to avoid the contamination of surgical wounds
by foreign pathogens and to reduce the risk of postoperative infections, thereby promoting a more
predictable regeneration [189–191].
4. Porous Scaffolds for Bone Grafting and Periodontal Tissue Engineering
Ideally, grafting materials for the alveolar bone should be shapable in different forms, depending
on the specific application, defect size and preference of the dental surgeon, and act as a template
(scaffold) for the growth of regenerated tissue in 3D [31]. Scaffolds should fill the void space,
avoiding the collapse of the defect, promote cell, platelet and vessel infiltration, be easy to manage,
and degrade at a rate comparable with new bone growth. The chemical composition and final
morphology are considered as the main players determining scaffolds characteristics like mechanical
properties, porosity, and degradability. Porosity is the crucial feature as all other parameters strongly
depend on it [192]. Hence, many studies have been carried out to understand which pore size,
pore distribution, and pore interconnectivity are preferable for promoting osteoblast proliferation and
bone ingrowth [193].
The scaffolds used as bone grafts should be not only osteoconductive but also osteoinductive,
thereby stimulating cells to proliferate and differentiate [194,195]. In order to achieve an optimal
osteointegration, the scaffold material should mimic as close as possible the bone morphology
following a biomimetic approach. Natural bone is mainly composed of HA crystals deposited in a
collagen matrix (biocomposite) [196] and can exhibit either a trabecular (porosity within 50–90 vol %,
pore size up to 1 mm) or a dense morphology (cortical bone, with a porosity in the range of 3 to
12 vol %) [197–199]. The mechanical properties of human bone broadly vary by age and depending on
the harvesting site in the body [199].
It has been well-documented that not only total porosity but also pore size of scaffolds have a
crucial role in bone formation in vitro and in vivo [193]. The morphology and porosity of the bone
graft also influence the osteogenesis, the mechanical properties, and the degradation rate: typically,
higher the porosity, lower the strength and elastic modulus, and faster the resorption rate (due to the
higher specific surface area) [200,201].
Numerous techniques have been developed to fabricate porous scaffolds, such as gas
foaming [202], salt leaching [203], phase transformation [204], freeze-drying [205], sponge
replication [206] as well as the recently-developed additive manufacturing methods [207].
The processing technique depends on the specific material(s) used and should be carefully optimized
to obtain an interconnected porosity with controlled pore size.
The key role played by porosity in bone regeneration was well pointed out by Kuboki et al. using
a rat ectopic model implanted with porous and dense HA particles [200]. The results showed no
new bone formation on the dense particles, whereas porous particles could promote the formation
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of new bone tissue. Hulbert et al. [208] first defined the pore diameter of 100 µm as the lowest
limit for osteogenic promotion. In this study, calcium aluminate scaffolds with different pore sizes
and a constant porosity of 46 vol % were implanted in dog femurs, and no bone ingrowth was
observed in the implant having pores smaller than 100 µm, whereas there was the highest new bone
formation in the samples having a pore size within 150–200 µm. These results are in agreement with
the diameters of the Haversian bone system, which reach values around 100–200 µm, and were then
confirmed by most studies carried out in the next years. There is also a minority of works reporting no
significant difference, regarding bone regeneration, between scaffolds having pores lower or higher
than 100 µm [200,209,210]. As a general comment, the variability of these results can be partially
justified by the different experimental conditions used, e.g., different materials, implantation site,
and animals just to mention a few ones. A very comprehensive and acute analysis of these issues has
been recently reported by El-Rashidy et al. [211]. Comparison between in vitro and in vivo results is
even much more difficult due to the reasons mentioned above.
The effects of porosity and pore size were evaluated in vitro using osteoblasts and mesenchymal
stem cells [212,213]. Small-sized pores allow cell aggregation and inhibit cell proliferation, resulting
in an increased expression of ALP and osteocalcin [214]. On the contrary, macropores allow cell
proliferation since large pores enhance nutrient and oxygen transportation. Very interestingly, in vitro
osteogenesis does not seem to be affected by pore size but is promoted by a low pore fraction [193].
Akay and coworkers evaluated the effect of pore size using primary rat osteoblasts and reported that
the samples with smaller pores could support cell growth, proliferation, and migration better than
their counterparts with large pores. Nonetheless, they observed no significant difference between the
two samples regarding the mineralization [213].
A multitude of variables characterize the in vivo scenario: for example, osteogenesis strongly
depends on the degree of vascularization, which is favored by high porosity (in contrast with in vitro
observations [193]) and large pore size to allow blood vessel access and development. It was shown
that small pores (below 100 µm) promote chondrogenesis before osteogenesis and low porosity, being
often characterized by non-interconnected pores, does not permit nutrient transportation [215–217].
It has been demonstrated that high porosity and large interconnected pores promote both in vivo
osteogenesis by the recruitment of osteoblastic cells, which are stimulated to migrate into the scaffold,
and vascularization that is the key to favor new bone formation [193]. In this regard, porous HA
scaffolds with different pore sizes were implanted subcutaneously in rats, and the results showed
an increase in the ALP activity for the material with pore sizes within 300–400 µm, along with good
capillary infiltration of fluids and cells [216,218].
Pore geometry also affects bone regeneration: long channels and interconnected spheroidal pores
promote cell colonization and bone ingrowth, while curved pores with poor interconnections on the
surface of the scaffold (like surface ‘pits’) hinder osteoblast precursor cell penetration and capillary
infiltration, thus allowing bone formation only on the scaffold surface [215].
The degree of porosity, pore size, and pore interconnectivity are key determinants for the
mechanical scaffold properties. It should be considered that, on the one hand, high porosity and
large pore size result in the promotion of bone ingrowth but, on the other hand, a high void volume
reduces the mechanical properties (primarily strength and stiffness) and is dangerous for the structural
integrity of the scaffold [219].
It is essential to take measures on the degradation rate of the material(s) used to produce the
scaffold; if the material has a fast degradation rate, the initial porosity should not be too high because
the rapid erosion of the scaffold struts could negatively affect the mechanical and structural integrity
of the implant before it is substituted by newly formed bone. On the other hand, if the degradation
rate of the biomaterial is low and the mechanical strength is high, it is possible to introduce a high
percentage of voids in the scaffold as the presence of channels and interconnected pores is considered
as one of the main reasons for the accelerated degradation due to macrophages (via enzymatic lysis)
and/or hydrolysis.
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The simultaneous presence of both micro- and macropores in the scaffold structure is
recommended, as relatively small pores below 100 µm promote protein adsorption and cell aggregation,
and large pores allow vascularization and new bone ingrowth [220]. Furthermore, the mechanical
properties and degradation rate can be finely tailored through providing a balance between large and
small pore.
Ceramic materials are often combined with natural polymers to control and customize the
mechanical properties and the degradation kinetics [221]. Furthermore, depositing a natural protein
layer (e.g., collagen and hyaluronic acid [116]) on the surface of a ceramic graft provides the scaffold
with biomimetic properties, thus enhancing the osteointegration. In this regard, the deposition of
the coating according to a layer-by-layer strategy could be useful to embed and then release drug
molecules in situ (Figure 4).J. Funct. Biomater. 2019, 10, x FOR PEER REVIEW  14 of 35 
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In general, dental surgeons prefer to use moldable fillers rather than porous but rigid implants
to press th material more easily into the defects [223]. Ceramic particles are either mixed with the
patient’ blood or combined with natural polymer to produce an injec able composite, which can fill
irregular defects tiny voids around itanium i plants that are otherwise difficult t reach. In the
presenc of large bone defects, however, the use of 3D porous sc ffolds can be recommended to
sustain th surr unding tissues and stimulat bon regeneration adequately. Iviglia et al. [206] r cently
developed a 3D multifunctional porous scaffold that is potentially suitable for periodontal reg neration
as w ll as to contrast peri-prosthetic infections around dental implants. Th s scaffold was produced by
sponge replication using HA and β-TCP powders (25: 75 w %) and was coated with a pectin/chitosan
PEI that acted as a carrier fo vancomycin. Taking the advantages of this method, the uthors could
obtain con rolled antibiotic release, and the results f serial bacterial dilution test after one week
proved tha the scaffold still inhibited the g wth of Staphylococcus epidermidis. Compressive strength
was adequate for safe handling during surgery (above 1 MPa), and egradation tests showed an
excell nt behavior in physiological and cidic environments (m ss loss <10% in the latter case, which is
typical of infecti s). Furthermore, the PEI coating showed an anti-inflamm tory r sponse, and good
pr liferation of osteoblastic cells (Saos-2 cell line) was observed in vitro.
The sa e research group develope a moldable chitosan/pectin hydrogel scaffold reinforced
with biphasic calcium phosphate particles within 100–300 µm. The polysaccharide nature of the porous
hydrogel matrix mimicked the natural bone ECM, and the ceramic articles promoted high osteoblast
proliferation; these characteristics, coupled it the easy adaptability to the defect dimensions,
make this material highly pro ising for alveol r regeneration (Figure 5).
Han et al. [224] also proposed to exploit the therapeutic ions released from implantabl
scaffold for stimulating and directing the biolo ical ctivity of the cells inv lved in periodontal
regeneration. Specifically, lithium ions incor rated into (and then delivered from) mesoporous
bioactive glass (MBG) scaffolds were shown to promote the attachment, proliferation an cement genic
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differentiation of human periodontal ligament cells via activation of Wnt/b-catenin signaling pathway
(Figures 6 and 7).J. Funct. Biomater. 2019, 10, x FOR PEER REVIEW  15 of 35 
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5. Guided Tissue Regeneration (GTR) Membranes  
As previously mentioned, the Melcher’s hypothesis states that certain cell types under the 
appropriate conditions can populate the periodontal wound and regenerate new cementum, 
alveolar bone, and periodontal ligament [24]. This process occurs when epithelial cells or fibroblast 
cells from the gingival front and connective tissue are excluded from the wound space. This goal can 
be achieved by developing a barrier membrane, which guides soft tissue regeneration without 
down-growth in the defect site [32]. Some necessary characteristics are counted for GTR membranes 
including compatibility with the living systems, cell exclusion, space maintenance, tissue 
integration, and easy use. The capabilities of separating the gingival flap from the coagulum in the 
wound space, of withstanding the masticatory stress and the flap tension, and of avoiding the 
collapse of the soft tissue while maintaining the space for the regeneration of new alveolar bone are 
all accounted as other important functions of the membrane, too [42]. Furthermore, bio-integration 
of GTR membranes ensures the stabilization of the wound and guides fibroblast cells to regenerate 
soft tissue without a down-growth in the periodontal defect space. As the final point, the easy use 
and handling of the membrane, required by dental surgeons during the operative procedures, are 
undoubtedly essential parameters for the GTR membrane. In the early 1980s, cellulose acetate filter 
was used as the first material in the role of a barrier membrane and its efficacy for the guided-tissue 
process was histologically proven [226]. Since then, different types of barrier materials have been 
developed and clinically experimented. 
5.1. Non-Resorbable Membranes  
The high mechanical stability and the capabilities of retaining the shape and inhibiting the cell 
migration process (from the gingiva in the wound site) are the main advantages of non-resorbable 
membranes [42]. In spite of the promising results obtained from the application of this type of GTR 
Figure 7. Effects of Li-doped B scaff l s t e expression of some of the bone-related genes such
as ALP (a), OPN (b), OCN (d), ce entu -specific arkers of CEMP1 (c), and CAP (e) for hPDLCs.
*: significant difference (p < 0.05) for the 5Li-MBG group in comparison to the other two groups at day 3.
**: significant difference (p < 0.05) for the 5Li-MBG group in comparison to the other two groups at
day 7. Reproduced with permission from [224].
5. Guided Tissue Regeneration (GTR)
As previously mentioned, the lc r’s othesis states that certain cell types under the
appropriate conditions can populate the periodontal wound and regenerate new cementum,
alveolar bone, and periodontal liga ent [24]. This process occurs when epithelial cells or fibroblast
cells from the gingival front and connective tissue are excluded from the wound space. This goal
can be achieved by developing a barrier membrane, which guides soft tissue regeneration without
down-growth in the defect site [32]. Some necessary characteristics are counted for GTR membranes
including compatibility with the living systems, cell exclusion, space maintenance, tissue integration,
and easy use. The capabilities of separating the gingival flap from the coagulum in the wound
space, of withstanding the masticatory stress and the flap tension, and of avoiding the collapse
of the soft tissue while maintaining the space for the regeneration of new alveolar bone are all
accounted as other important functions of the membrane, too [42]. Furthermore, bio-integration of
GTR membranes ensures the stabilization of the wound and guides fibroblast cells to regenerate
soft tissue without a down-growth in the periodontal defect space. As the final point, the easy
use and handling of the me brane, required by dental surgeons during the operative procedures,
are undoubtedly essenti l parameters for the GTR me brane. In the early 1980s, cellulose acetate filter
was us d as the first material in the role of a barri r membrane and its efficacy for the guid d-tissue
process was histo ogica ly proven [226]. Since then, different types of barrier materials have been
developed and clinically experimented.
5.1. Non-Resorbable Membranes
The high m chanical stability and the capabilities of re aining the shape and i hibiting the cell
migration process (from the gingiva in the wound site) are the main adv ntages of non-resorbable
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membranes [42]. In spite of the promising results obtained from the application of this type of
GTR materials, there are some critical drawbacks regarding the need for a second surgery and the
possible interference with the healing process, which can be overcome only by using resorbable
membranes. Polytetrafluorethylene (ePTFE) and titanium-reinforced PTFE meshes are the most
commonly-implanted non-resorbable membranes.
The ePTFE (Goretex®) membrane was the first GTR membrane approved for clinical use in the
1990s [227]. ePTFE is chemically identical to PTFE and exhibits a porous microstructure that allows
connective tissue ingrowth. ePTFE membranes for GTR have a typical bi-layered structure: the first
layer, which is porous (90 vol %) and around 1-mm thick, can promote cell ingrowth, whereas the
second layer (thickness 0.15 mm, porosity 30 vol %) acts as a space provider for regeneration, inhibiting
the epithelial cell down-growth and giving structural stability [228,229]. Goretex® membrane possesses
an exceptional inertness as it does not elicit any foreign body reaction. Several clinical trials have been
carried out on this material, and histological observations revealed that ePTFE membrane could lead
to significant periodontal regeneration after a three-month healing period [228,230]. Some other works,
however, report no significant difference between the results obtained from treatment with ePTFE
membrane and the conventional debridement therapy with open flap. Moreover, some reports stated
that there are some additional complications associated with ePTFE GTR membranes, like pain and
purulence, along with additional costs for a second surgery if needed [231].
The ePTFE membrane can also be reinforced with a titanium mesh between the two layers
to increase the mechanical strength and the supporting function to tissues [42,232]. It has been
shown that the addition of a titanium mesh to the membrane can be useful for achieving the better
positioning under the flap by the dental surgeon and for increasing the stability of the membrane,
thus preventing defect collapse. Although the microporosity of the membrane avoids cell ingrowth,
it can permit fluid infiltration. The results of animal experiments indicated relevant cementum and
bone regeneration [233,234]; however, no difference was observed between titanium-reinforced and
titanium-free ePTFE GTR membranes in clinical trials [232,235]. Furthermore, the main disadvantage
is the increased risk of exposure due to titanium stiffness, which is associated with a more complex
secondary surgery to remove the implant [236].
The future of periodontal tissue regeneration is the development and use of biomaterials which
can degrade during tissue formation without the need for being removed by any further surgical
procedure, thereby reducing patient’s pain, stress, and hospitalization costs.
5.2. Resorbable Membranes
Owing to the need for a second surgery to remove non-resorbable membranes, in the last
decade, the demand for bioabsorbable membranes with comparable and in some aspects better
clinical outcome became urgent. Resorbable membranes were thought suitable to reduce the patient’s
overall discomfort and, if provided with bioactive properties, to accelerate tissue healing compared to
non-resorbable ones [42]. General disadvantages of these materials include the only partly predictable
resorption rate, due to the different degradation processes that could take place (enzymatic or by
hydrolysis), and the risk of eliciting local inflammation due to degradation [32]. Resorbable membranes
can be obtained from natural sources or by synthetic procedures. Natural membranes have the
advantages of being highly biocompatible and potentially bioactive, but typically lack mechanical
properties and tend to degrade very rapidly in vivo [42,237]. On the other hand, synthetic materials
show a more predictable behavior as their degradability and mechanical properties can be tuned by
acting on the composition. However, this may result in a foreign body reaction.
As aforementioned, the periodontal connective tissue is mostly made of type I collagen that
has been widely used in periodontology due to low immunogenicity, ability to attract and activate
periodontal ligament/gingival fibroblast cells, and hemostatic properties [150]. The interaction
with various cell types demonstrates the bioactivity of collagen and its potential to augment tissue
thickness during the healing process (Table 1). Up to now, some collagen-based membranes have
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been commercially produced, such as BioOss® membrane (Geistlich Pharma, Wolhusen, Switzerland)),
OsteoBiol® (Tecnoss, Giaveno, Italy), Zimmer BioMend® and BioMend Extended® (Zimmer, Frankfurt,
Germany) and Lyoplant® (Braun AG, Melsugen, Germany). The behavior of the collagen GTR
membranes is determined by the source of the collagen and on the process used to obtain it [238].
Table 1. Selected examples of commercially available collagen-based membrane for GTR
Commercial
Name Company Sources
Cross-Linking
Agent Main Components
Resorption
Rate
BioMend Zimmer, Frankfurt,Germany Bovine tendon Formaldehyde 100% type I collagen 6–8 weeks
BioMend-Extend Zimmer, Frankfurt,Germany Bovine tendon Formaldehyde 100% type I collagen 18 weeks
Periogen Collagen Inc., PaloAlto, CA Bovine dermis Glutaraldehyde Type I and III collagen 4–8 weeks
Paroguide Coletica, Lyon, France Clafskin DPPA 96% type I collagen and 4%chondroitin-4-sulfate 4–8 weeks
Biostite Coletica, Lyon, France Calfskin DPPA
88% HA 9.5% type I
collagen, and 2.5%
chondroitin-4-4sulfate
4–8 weeks
BioGide Geistlich, Wolhusen,Switzerland Porcine dermis None Type I and III collagen 24 weeks
Tissue Guide Koken Co., Tokyo, Japan Bovine dermis+ tendon HMDIC
Atelocollagen (I◦) + tendon
collagen 4–8 weeks
BioBar
Colbar Research & Dev.
Ltd., Ramat-Hasharon,
Israel
Bovine dermis N/A 100% type I collagen 6–8 moths
Osteobiol Tecnoss srl, Giaveno,Italy
Heterologous
mesenchymal
tissue
None 100% equine collagen 8 weeks
Sources such as skin, tendons, or bovine/porcine pericardium are usually used for collagen
extraction [150]. According to the European Union’s guidelines, collagen extracted from animal
sources needs to be chemically purified to eliminate all viral and bacterial contaminants. In this regard,
the antigenicity of collagen should be eliminated by removing lipid and non-collagenous protein
remnants. Sequential segment analysis, biocompatibility, and sterility are checked step by step [32].
The most common post-purification modification process of collagen is the chemical crosslinking,
which improves its mechanical strength and reduces its degradation rate and water uptake capacity.
However, this process is usually associated with increased cytotoxicity due to the possible presence of
crosslinking traces inside the collagen network [152]. Degradation of collagen is due to the action of the
enzyme collagenase that cuts the collagen chain and transforms it into gelatin, which is then degraded
via amino acid gelatinases [32,150]. Based on the source and the crosslinking processes, the resorption
time of collagen GTR membrane varies from 1 to 6 months [239,240]. Non-resorbable ePTFE GTR
membrane was compared to collagen membrane, and the results showed that the latter stimulates
the proliferation of gingival fibroblasts and the ECM synthesis in a significantly higher amount [235].
Wang et al. observed a better osteoblast attachment on collagen surfaces while the collagen membrane
remained intact and prevented the apical proliferation of epithelial cells [241]. Animal studies using
BioOss® revealed that the collagen-based membrane could regenerate the periodontal tissue, and the
material resorbed after eight weeks. Also, during the resorption, a small inflammatory zone was
visible around the implant, which finally disappeared after total resorption [79,239].
The main drawbacks of collagen membranes include limited toughness and low space
maintenance [32,242]. Therefore, there is still the need for developing a man-made material that
can swell and fill the irregular shape of the gingival flap in order to stabilize the membrane;
moreover, this capability should be coupled with antiadhesive properties which guide epithelial
regeneration without eliciting inflammatory reactions and preventing cell in-growth in the wound
defect. Organic aliphatic thermoplastic polymers—such as poly(lactic acid), poly(glycolic acid),
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and their copolymers—are the most commonly-used synthetic materials in GTR. The great advantage
of using synthetic polymers concerns the ease of customizing some properties, such as degradation
kinetics and mechanical properties, by varying the length of the chain and the amount of lactide or
glycol units [243]. The most important drawback associated with man-made materials is the significant
increase of pH values arising from the by-products released during the hydrolysis, which can cause
cytotoxic effects [244]. Furthermore, bulk degradation of these materials is another limitation as it can
lead to decreased mechanical stability and interfere with periodontal regeneration. There are some
commercial synthetic products for GTR available on the market; historically, the first of them to appear
on the market in the 1990s was Guidor® (Sunstar Americas Inc., Schaumburg, IL, USA), which is
a bilayer membrane made of poly(lactic acid) and citric acid ester acetyl tributylcitrate. The outer
layer of Guidor® has rectangular perforations in which new tissue can grow, while the internal layer
has smaller circular perforations and outer space to maintain the distance between the membrane
and the root surface [42,245]. An internal spacer between the two layers promotes tissue ingrowth.
The results of animal experiments revealed that complete resorption of the membrane occurs within
12 weeks, even if the immune system initially detected the membrane as a foreign body. Over the years,
a large number of other products have been developed, such as Resolute® (W.L. Gore & Associates,
Flagstaff, AZ, USA), made of poly(lactic-co-glycolic acid) co-polymer reinforced with polyglycolide
fibers [246], Vycril Periodontal Mesh® (Ethicon, Somerville, NJ, USA), made of a co-polymer of lactide
and glycolide [247], and Atrisorb® (Tolmar Inc., Fort Collins, CO, USA), which is produced in flowable
poly(lactic acid) and is ready to use after exposure in saline solution for 6 minutes [248]. All the
mentioned membranes have been evaluated both in vitro and in vivo, and the results have revealed
their great potential regarding the stimulation of periodontal regeneration, although many of them
elicit foreign-body reaction associated with the release of acidic by-products [42]. In addition to the
above-mentioned polyester membranes, polyurethane membranes which degrade via enzymatic lysis
have also been proposed [249]. Animal studies showed that these membranes could elicit inflammatory
responses and their degradation was slower compared to poly(lactic acid) [250]. Cell response
to polyurethane membrane obtained from plant-derived oil was found similar to that of PTFE
non-resorbable membrane [230].
6. Growth Factors in Periodontal Tissue Engineering
The incorporation of bioactive molecules into periodontal biomaterials and scaffolds and
their local and controlled release over time has been proposed as a valuable approach to obtain
osteoinductive implants [251]. Two different procedures to embed growth factors are available, i.e.,
either during the preparation of the material [252] or after the fabrication [253,254]. Platelet-rich
growth factor (PDGF), bone morphogenetic proteins (BMPs), and enamel matrix derivatives (EMDs)
are among the most potent biomolecules for accelerating the periodontal wound repair in preclinical
and clinical studies [251,255–257]. Growth factors have the potential of stimulating the interaction
between mesenchymal stem cells (MSCs) and epithelial stem cells during tooth formation, along with
all the following processes such as collagen formation, mineralized matrix deposition, and fibroblast
proliferation [251,258]. The morphology of the scaffold where signaling molecules are incorporated is
fundamental to achieve an extended and effective release. The incorporated molecules are released
according to a diffusion mechanism which strongly depends on the porosity—especially the pore
interconnectivity—of the material. The degradation properties of the graft or GTR membrane also
affect the release rate of growth factors, which might be faster because of the high solubility of the
matrix. Furthermore, the way in which the carrier degrades—either by surface or by bulk degradation,
resulting in a controlled or burst release, respectively—plays a key role, too [259–261]. The research
and development process addressed to produce a commercial product containing growth factors is
expensive and difficult to regulate; however, it is clear that growth factors have a significant impact on
tissue engineering outputs which deserves to be explored.
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6.1. Platelet-Rich Growth Factor (PDGF)
PDGF is the main growth factor involved in wound healing, and there is a lot of in vitro and
in vivo studies showing its ability to enhance the proliferation and migration of periodontal ligament
cells. PDGF is naturally made of the conjugation of polypeptides of growth factor-BB and growth
factor-AA, which encoded by two different genes. It has been demonstrated that all isoforms have
an effect on cell proliferation in vitro [262,263]. It has been shown that PDGF has a chemotactic
effect, by which it can promote collagen synthesis, and stimulates hyaluronate synthesis by gingival
fibroblasts and fibroblast proliferation. Furthermore, if added to a culture with osteoblast-like cells,
PDGF can regulate the ALP and osteocalcin expression [264]. Lynch et al. [265] applied PDGF in
combination with the insulin-like growth factor-1 (IGF-1) in dogs, and the results demonstrated great
effectiveness in periodontal regeneration. Furthermore, the results of clinical trials revealed that the
synergistic effect of these two growth factors could lead to the stimulation of bone regeneration in
periodontal defects in humans, too [266]. Even if used alone, PDGF can significantly stimulate the
formation of new cementum and the production of collagen [267]. Molecular cloning and large-scale
purification have permitted the production of recombinant human PDGF, which has been mixed with
β-TCP and made commercially available to clinicians (GEM 21s®, Osteohealth, Shirley, NY, USA) [268].
6.2. Bone Morphogenetic Proteins (BMPs)
BMPs belong the superfamily of transforming growth factor-beta (TGF-β) [251,268]. They are
abundant proteins in the bone tissue and are produced by many cell types such as osteoblasts. BMP-2,
-4, and -7 are typically retained in bone allografts that are therefore osteoinductive and can actively
influence cell behavior in vivo. Some animal and human studies have given convincing evidence of
the great potential of BMPs in periodontal regeneration with a significant acceleration of alveolar bone
healing [269–271]. BMPs encourage the division and chemotaxis of undifferentiated mesenchymal
stem cells (MSCs) and osteoblast precursors through activating the expression of genes involved in
bone formation (e.g., osteocalcin and ALP) [272]. The production of synthetic BMPs is very expensive,
which limits their incorporation and use in synthetic biomaterials.
6.3. Enamel Matrix Derivatives (EMDs)
The ideal purpose of dental surgeons is achieving periodontal regeneration by mimicking
the natural process that takes place during tooth formation. It has been demonstrated that the
Hertwig’s cells are responsible for the secretion of enamel matrix proteins during the development
of a nascent root and periodontal tissue. These proteins are then deposited onto the root surface
and provide an initial and essential step that influences the migration of the surrounding cells and
the formation of cementum, periodontal ligament, and alveolar bone [273,274]. The observation of
this protein layer between the peripheral dentin and the cementum resulted in the development
of EMDs in the form of purified acid extracts of proteins from pig enamel matrix (Emdogain®,
Strauman AG, Basel, Switzerland) [275,276]. The main component of EMD is amelogenin, which is a
specific ECM protein directing the mineralization of enamel [257]. Amelogenin, under physiological
conditions, is assembled into nanospheres to form ECM, which during enzymatic degradation by
metalloproteinases releases bioactive peptides for weeks [43,258]. This process stimulates new bone
formation, root resorption, and wound healing. EMD can mimic odontogenesis by the recruitment
and stimulation of cementoblasts to form the root cementum on the root surface [277]. Then,
the newly-formed root cementum will lead to the regeneration of periodontal fibers and alveolar bone.
Emdogain® was clinically applied for the first time in 1997 [276], and it is currently the unique product
on the market that, used alone, has the potential for triggering significant regenerative responses in
periodontal ligament cells. Cambini et al. [278] recently highlighted the easiness of application of
amelogenin, its persistence in situ for two weeks, and their exceptional osteoinductive capability, which
made unnecessary the use of barrier materials. A systematic literature review conducted by Batistin
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Zanatta et al. [279] also suggests that EMDs are associated to better clinical outcomes compared to
conventional treatments, but the heterogeneity and experimental differences of the studies published
in the literature make definite conclusions difficult to draw.
7. Gene Therapy Approach in Periodontology
The critical drawbacks associated with the local delivery of growth factors include their short
biological half-life in vivo as well as high cost [256,280]. Even most importantly, using a high dosage
of bioactive molecules is needed to promote tissue regeneration, which could lead to unpredictable
reactions and side effects; hence, an alternative approach to the local release of growth factors is the use
of gene therapy for periodontal regeneration [280]. Gene therapy involves the insertion of the genes of
interest into an individual’s cells to obtain the desired functions, i.e., in most cases, upregulation of the
expression of a specific growth factor [38,255,281]. For this purpose, two main strategies have been
proposed and developed including (i) in vivo technique, in which the gene vector is directly inserted
into the target site [280,282], and (ii) ex vivo technique, in which selected cells are harvested, expanded,
genetically transduced, and eventually re-implanted [283].
Gene therapy has been applied for the upregulation of the expression of PDGF [284–286] and
BMPs [287]. In the in vivo technique the gene of interest is directly delivered in the body, thus altering
the normal expression of the target cells. On the contrary, the ex vivo technique involves the use of an
adenovirus vector to introduce the genetic material into the target cells that have been harvested by a
biopsy; eventually, transfected cells are re-implanted in the periodontal defect [256,288]. In spite of the
great potential of these techniques, there are several concerns about the safety of the adenovirus vector
that still currently limit the clinical applicability of the gene therapy approach [281,289].
8. Nanobiomaterials and Functionally-Graded Implants: The Last Frontiers in Periodontal
Tissue Engineering
Periodontal regeneration involves a set of complex tissues and structures in and around the tooth;
hence, an ideal biomaterial-driven approach should include a functionally-graded scaffold where the
chemical composition and 3D architecture of each layer (or ‘compartment’) match the fine organization,
biochemical composition, and mechanical properties of the tissues to regenerate. This valuable strategy
is in its beginning in the whole field of tissue engineering—not restricted to dentistry—and shows
a great promise for the 21st-century regenerative medicine. The existing examples of multi-layer
scaffolds for multi-tissue regeneration often involve the use of nanomaterials, which can more closely
reproduce the fine characteristics of the structure to regenerate [290].
Sowmya et al. [291] recently reported the development of a 3-layer scaffold for the simultaneous
regeneration of cementum, alveolar bone, and periodontal ligament. Specifically, this scaffold was
structured as follows: chitosan/poly(lactic-co-glycolic acid) (PLGA)/nano-sized bioactive glass layer
loaded with cementum protein 1 (CEMP1) for the cementum regeneration, chitosan/ PLGA layer
loaded with fibroblast growth factor 2 for periodontal ligament regeneration, and chitosan/PLGA
/nano-sized bioactive glass layer loaded with platelet-rich plasma (PRP) growth factors for bone
regeneration. Histological and tomographic evaluations showed that the implantation of this scaffold
in rabbits led to complete periodontal healing and new alveolar bone deposition after three months.
Incorporation of growth factors further stimulating tissue regeneration in nanomaterial-based
constructs was also investigated. Zhang et al. [292] fabricated MBG/silk fibroin scaffolds incorporating
BMP-7 and/or PDGF-B adenovirus and implanted them in dogs. The scaffolds loaded with PDGF-B
adenovirus were able to partially regenerate the periodontal ligament while those loaded with
BMP-7 primarily improved new alveolar bone formation. The synergistic combination of these
two growth factors promoted periodontal healing by allowing up to two times greater regeneration of
the periodontal ligament, alveolar bone, and cementum as compared to each adenovirus used alone.
Chen et al. [293] used a poly(ε-caprolactone) (PCL)-based multiphasic scaffold, enriched with type
I collagen, as a carrier to release CEMP1-loaded poly(ethylene glycol) (PEG)-stabilized amorphous
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calcium phosphate nanoparticles. After implantation in rats for eight weeks, these scaffolds were
shown able to stimulate cementum-like tissue formation but little new bone regeneration.
None of these scaffolds was experimented in humans yet, probably due to the lack of clear
evidence about the effects of growth factors in the long term and the fate of nanomaterials used in vivo,
as well as the high cost of the devices.
9. Discussion and Conclusions
Periodontium refers to the specialized tissues that both surround and support the teeth,
maintaining them in the maxillary and mandibular bones [25,26]. Tooth loss is a possible consequence
of trauma or periodontal disease, such as gingivitis, periodontitis, or tissue decay [45]. The scope of
periodontal tissue engineering is to regenerate the tooth’s supporting tissue through a combination of
proper biomaterials, which stimulate cells and signaling molecules to produce new healthy tissue [8].
Many advances have been made in the last decade in the regeneration of complex periodontal and
alveolar bone defects [268]. Research efforts in polymeric and ceramic scaffolding systems for cell,
protein, drug, and gene delivery have led to the development of complex and often multifunctional
implants with a predictable response. In the research world, there is still some debate as to the best
treatment modality for obtaining periodontal regeneration [6]. Some groups advocate the use of
bone replacement grafts alone, whereas others suggest that a guided tissue membrane (GTR) alone
might be sufficient, and still others recommend a combination of both. Tobon et al. [294] conducted
a study comparing three different treatment modalities for achieving periodontal regeneration and
GTR after endodontic surgery: one control group without bone graft and membrane, one group
treated with bone graft alone, and another group treated with both bone graft and membrane.
They used a non-resorbable material as a membrane and HA as a bone graft. The results showed
that the best periodontal regeneration was assessed through the combination of both membrane and
bone graft. The worst results were obtained in the control group, where no membrane nor graft
were used. Yoshikawa and co-workers [295] compared the histological outcome of different types of
membranes—i.e., non-resorbable ePTFE, resorbable PLGA, and resorbable collagen membrane—and
found that the greatest amount of bone regenerated was achieved using non-resorbable membranes.
Another group, comparing an open flap debridement with a bone allograft and a bone allograft with
a collagen membrane in an animal study, showed similar results in terms of bone formation in all
cases [296]. The studies mentioned above showed different and even contrasting results, and each
of them suggests different approaches in order to achieve an excellent periodontal regeneration.
In general, case selection is very important to the success of regenerative strategies, which might
explain some of the inconsistencies in the literature [6]. Factors that affect clinical success can be
related to the specific patient, specific disease and healing categories. The success of a surgical
procedure involving the use of a bone grafting material, a GTR membrane or else a combination of both,
also depends on good plaque control, compliance, non-smoking, anti-infective therapy, and systemic
health [297–299]. Furthermore, also during the surgical procedures, there may be additional variables
which could affect the results of the regeneration process, such as the possible infection of the implanted
material, which could cause peri-prosthetic infection.
In summary, periodontal regeneration still remains a partially unmet challenge. The incorporation
of growth factors in periodonatal bioamterials and scaffolds is indeed a valuable strategy to improve
regeneration, but biomolecules are typically expensive, which makes them accessible just to a minority
of patients, and can elicit unpredictable side effects even at low dosage. Gene therapy has opened
up new horizons to treat congenital dental diseases in individuals and their offspring; however, viral
vectors used in these methods could elicit immune responses with irreversible damages. Loading and
controlled release of therapeutic ions, which can stimulate the genes of cells towards paths of targeted
tissue regeneration and self-repair, could be a highly-attractive alternative deserving investigation
in the near future. Furthermore, the development of functionally-graded scaffolds mimicking the
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composition and microstructural organization of the tissues to regenerate represent a key step towards
the simultaneous healing of multiple periodontal tissues.
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